Home
/
Jazz Pharmaceuticals plc
/
Financials
/
Quarterly
Jazz Pharmaceuticals plc — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Jazz Pharmaceuticals plc filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$444.61M
May 8, 2018
Q3
2017
Sep 30, 2017
$411.86M
Nov 7, 2017
Q2
2017
Jun 30, 2017
$394.39M
Aug 8, 2017
Q1
2018
Mar 31, 2017
$376.05M
May 8, 2018
Q3
2017
Sep 30, 2016
$374.18M
Nov 7, 2017
Q2
2017
Jun 30, 2016
$381.16M
Aug 8, 2017
Q1
2017
Mar 31, 2016
$336.01M
May 9, 2017
Q3
2016
Sep 30, 2015
$340.87M
Nov 8, 2016
Q2
2016
Jun 30, 2015
$333.75M
Aug 9, 2016
Q1
2016
Mar 31, 2015
$309.30M
May 10, 2016
Q3
2015
Sep 30, 2014
$306.58M
Nov 9, 2015
Q2
2015
Jun 30, 2014
$291.23M
Aug 5, 2015
Q1
2015
Mar 31, 2014
$246.92M
May 7, 2015
Q3
2014
Sep 30, 2013
$232.16M
Nov 4, 2014
Q2
2014
Jun 30, 2013
$208.25M
Aug 5, 2014
Q1
2014
Mar 31, 2013
$196.24M
May 8, 2014
Q3
2013
Sep 30, 2012
$175.52M
Nov 5, 2013
Q2
2013
Jun 30, 2012
$124.23M
Aug 6, 2013
Q1
2013
Mar 31, 2012
$102.53M
May 7, 2013
Q3
2012
Sep 30, 2011
$73.29M
Nov 9, 2012
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.13B
Nov 5, 2025
Q2
2025
Jun 30, 2025
$1.05B
Aug 6, 2025
Q1
2025
Mar 31, 2025
$897.84M
May 7, 2025
Q3
2025
Sep 30, 2024
$1.05B
Nov 5, 2025
Q2
2025
Jun 30, 2024
$1.02B
Aug 6, 2025
Q1
2025
Mar 31, 2024
$901.98M
May 7, 2025
Q3
2024
Sep 30, 2023
$972.14M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$957.32M
Aug 1, 2024
Q1
2024
Mar 31, 2023
$892.81M
May 2, 2024
Q3
2023
Sep 30, 2022
$940.65M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$932.88M
Aug 9, 2023
Q1
2023
Mar 31, 2022
$813.72M
May 10, 2023
Q3
2022
Sep 30, 2021
$838.12M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$751.81M
Aug 3, 2022
Q1
2022
Mar 31, 2021
$607.58M
May 4, 2022
Q3
2021
Sep 30, 2020
$600.89M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$562.44M
Aug 3, 2021
Q1
2021
Mar 31, 2020
$534.73M
May 4, 2021
Q3
2020
Sep 30, 2019
$537.70M
Nov 2, 2020
Q2
2020
Jun 30, 2019
$534.13M
Aug 4, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$251.41M
Nov 5, 2025
Q3
2025
Jun 30, 2025
($718.47M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($718.47M)
Aug 6, 2025
Q2
2025
Mar 31, 2025
($92.54M)
Aug 6, 2025
Q3
2025
Mar 31, 2025
($92.54M)
Nov 5, 2025
Q1
2025
Mar 31, 2025
($92.54M)
May 7, 2025
Q3
2025
Sep 30, 2024
$215.06M
Nov 5, 2025
Q3
2025
Jun 30, 2024
$168.57M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$168.57M
Aug 6, 2025
Q1
2025
Mar 31, 2024
($14.62M)
May 7, 2025
Q2
2025
Mar 31, 2024
($14.62M)
Aug 6, 2025
Q3
2025
Mar 31, 2024
($14.62M)
Nov 5, 2025
Q3
2024
Sep 30, 2023
$146.82M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$104.44M
Aug 1, 2024
Q3
2024
Jun 30, 2023
$104.44M
Nov 7, 2024
Q2
2024
Mar 31, 2023
$69.42M
Aug 1, 2024
Q3
2024
Mar 31, 2023
$69.42M
Nov 7, 2024
Q1
2024
Mar 31, 2023
$69.42M
May 2, 2024
Q3
2023
Sep 30, 2022
($19.65M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
$34.67M
Aug 9, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$57.51M
Nov 5, 2025
Q2
2025
Jun 30, 2025
($686.39M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($55.89M)
May 7, 2025
Q3
2025
Sep 30, 2024
$260.21M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$199.44M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$66.21M
May 7, 2025
Q3
2024
Sep 30, 2023
$172.39M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$157.64M
Aug 1, 2024
Q1
2024
Mar 31, 2023
$126.06M
May 2, 2024
Q3
2023
Sep 30, 2022
$24.76M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$85.55M
Aug 9, 2023
Q1
2023
Mar 31, 2022
$87.55M
May 10, 2023
Q3
2022
Sep 30, 2021
$28.37M
Nov 9, 2022
Q2
2022
Jun 30, 2021
($69.59M)
Aug 3, 2022
Q1
2022
Mar 31, 2021
$162.12M
May 4, 2022
Q3
2021
Sep 30, 2020
$196.21M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$198.13M
Aug 3, 2021
Q1
2021
Mar 31, 2020
($189.67M)
May 4, 2021
Q3
2020
Sep 30, 2019
$133.10M
Nov 2, 2020
Q2
2020
Jun 30, 2019
$204.28M
Aug 4, 2020